 |
Dr. Reddy has listed a clinical trial to continue to investigate Topical Itraconazole 5% as a treatment for the papules and pustules of rosacea. So we can add DFD-04 to the list of new drugs in development for rosacea.
From Dr. Reddy’s 2015 Investor Day Presentation.
We target underserved segments within large disease areas both in Dermatology and Neurology.
Mid-stage dermatology assets
Rosacea: 16M sufferers, 0.8-1M Underserved Segment.
DFD-04: Phase 1, novel repurposed topical API for treatment of rosacea
Clinical Trial NCT02828241
A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
Sponsor: Dr. Reddy’s Laboratories Limited
Study start date: June 2016
Locations: Germany
From a related listed on clinicaltrials.eu, we can see that DFD-04 is topical Itraconazole 5%.
EudraCT Number: 2015-005486-23
DFD04-CD-002
A Placebo controlled study to test DFD-04 Ointment 5% in patients with rosacea over 12-weeks
A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of DFD-04 (itraconazole) Ointment, 5% in Patients with Inflammatory Lesions of Rosacea Over 12-weeks
Related Articles
- Promiseb Topical Cream for Seborrheic Dermatitis
- Metrogel also works for Seborrheic Dermatitis
- Sebclair for seborrheic dermatitis
- Malassezia Globosa causes seborrhea, Pyrithione Zinc is effective
- Xolegel for treating seborrheic dermatitis (seb derm)
- Cleansing your SD skin with a sonic brush (Clarisonic)
- Seb derm, elidel and protopic : a warning
- Seebazole (topical ketoconazole gel 2%) low systemic absorption for short treatment periods
- 9 New Drugs in Development for Rosacea
- New Rosacea Treatments – get them while they’re hot
